# Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

> **NCT07332351** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Washington** · enrollment: 33 (estimated)

## Conditions studied

- Muscle Invasive Bladder Urothelial Carcinoma
- Stage II Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Nadofaragene Firadenovec
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **PROCEDURE:** Radical Cystectomy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT07332351
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07332351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07332351, "Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07332351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*